BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7553142)

  • 1. [Long-term effect of leprosy control in both highly endemic prefectures, Weifang of Shandong and Wenshan of Yunnan].
    Li H; Weng X; Li T
    Zhonghua Yi Xue Za Zhi; 1995 Jun; 75(6):333-7, 381-2. PubMed ID: 7553142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of leprosy control in two Prefectures of China, 1955-1993.
    Li HY; Weng XM; Li T; Zheng DY; Mao ZM; Ran SP; Liu FW
    Int J Lepr Other Mycobact Dis; 1995 Jun; 63(2):213-21. PubMed ID: 7602216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-duration multidrug therapy in multibacillary leprosy.
    Li HY; Hu LF; Wu PW; Luo JS; Liu XM
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):230-7. PubMed ID: 9251596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiological shift in leprosy in a rural district of central India following introduction of multi-drug therapy (April 1986 to March 1992 and April 1992 to March 2002).
    Pandey A; Uddin MJ; Patel R
    Lepr Rev; 2005 Jun; 76(2):112-8. PubMed ID: 16038244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
    Mane I; Cartel JL; Grosset JH
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in detection of new leprosy cases at two centres in Himachal Pradesh, India: a ten-year study.
    Mahajan VK; Sharma NL; Rana P; Sood N
    Indian J Lepr; 2003; 75(1):17-24. PubMed ID: 15253391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
    Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
    Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in leprosy over fifty years in Gudiyatham Taluk, Vellore, Tamil Nadu.
    Norman G; Raja Samuel Bhushanam JD; Samuel P
    Indian J Lepr; 2006; 78(2):167-85. PubMed ID: 16927851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
    Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
    Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed resolution versus treatment failure in paucibacillary leprosy patients under six months fixed duration multidrug therapy.
    Job CK; Jayakumar J; Aschhoff M
    Indian J Lepr; 1997; 69(2):131-42. PubMed ID: 9290964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapsone drug resistance in the MDT era.
    Roche PW; Neupane KD; Failbus SS; Butlin CR
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens.
    Fajardo TT; Villahermosa L; Pardillo FE; Abalos RM; Burgos J; Dela Cruz E; Gelber RH
    Am J Trop Med Hyg; 2009 Aug; 81(2):330-4. PubMed ID: 19635893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends of case detection and other indicators of leprosy in China during 1985-2002.
    Shen JP; Gupte MD; Jiang C; Manickam P; Yu MW; Li WZ
    Chin Med Sci J; 2005 Jun; 20(2):77-82. PubMed ID: 16075742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
    Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
    Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in new case-detection leprosy in Bihar, India.
    Vijayakumaran P; Prasad B; Krishnamurthy P
    Indian J Lepr; 2006; 78(2):145-51. PubMed ID: 16927849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary appraisal of a WHO-recommended multiple drug regimen in paucibacillary leprosy patients in Malawi.
    Boerrigter G; Ponnighaus JM; Fine PE
    Int J Lepr Other Mycobact Dis; 1988 Sep; 56(3):408-17. PubMed ID: 3418206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.